Transfer of marketing operations and succession of marketing authorizations for ELOPLAT and other products
First written in FY2024-Q3. 3 of 4 entries say "Advanced", first in FY2024. Latest entry: FY2025.
4 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「For pharmaceutical products, the transfer of sales operations and succession of manufacturing and marketing authorizations were carried out sequentially for each product based on the basic agreement concerning oncology-related prescription drugs and their transfer to Takata Pharmaceutical Co., Ltd.」
The transfer of sales operations and succession of marketing authorizations to Takata Pharmaceutical moved into the implementation phase for individual products, and 4 products were removed from the National Health Insurance drug price list at the end of March 2025. - FY2025-H1AdvancedAnnual report
「Specifically, the transfer of marketing operations for the antineoplastic agent ELOXATIN was completed in May, and marketing operations for other products have been transferred sequentially since April. The company will continue to proceed with the transfer of marketing operations and succession of marketing approvals, while giving due consideration to all parties concerned.」
Regarding the transfer of sales operations and succession of manufacturing and marketing authorizations for oncology-related prescription drugs to Takata Pharmaceutical, the transfer of sales operations for “Elplat” was completed in May, and the process has moved to the stage of transferring other products in succession. - FY2024AdvancedAnnual report
「In October last year, we entered into a basic agreement concerning the transfer of sales operations and succession of manufacturing and marketing authorizations for oncology-related prescription drugs to Takata Pharmaceutical Co., Ltd. We are making planned preparations for the transfer of sales operations and succession of manufacturing and marketing authorizations for “Elplat” and other products, with due consideration for patients and all relevant parties.」
A basic agreement was signed concerning the transfer of sales operations and succession of manufacturing and marketing authorizations to Takata Pharmaceutical, and preparations moved into the planned implementation phase. - FY2024-Q3First statedAnnual report
「We are also making planned preparations, with due consideration for patients and all relevant parties, for the transfer of sales operations and succession of manufacturing and marketing authorizations for “Elplat” and other products to Takata Pharmaceutical Co., Ltd.」
New preparations were disclosed for the transfer of sales operations and succession of manufacturing and marketing authorizations for “Elplat” and other products to Takata Pharmaceutical Co., Ltd.